# Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

> **NCT02052908** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 81 (actual)

## Conditions studied

- Lynch Syndrome

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Naproxen
- **OTHER:** Placebo Administration

## Key facts

- **NCT ID:** NCT02052908
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-27
- **Primary completion:** 2019-10-25
- **Final completion:** 2021-01-05
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052908, "Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02052908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*